Head-to-head · free
Lexeo Therapeutics, Inc. Common Stock vs Mirum Pharmaceuticals, Inc.
LXEO vs MIRM — return on capital, cash generation, margins and balance sheet side by side.
LXEO
1 / 4
measures where LXEO leads
MIRM
3 / 4
measures where MIRM leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | LXEO · FY2025 | MIRM · FY2025 |
|---|---|---|
| Revenue | — | $521.3M |
| Net income | (100.0M) | (23.4M) |
| Revenue growth (yearly, multi-year) | — | 128.5% |
| Free cash flow | (99.0M) | $54.9M |
| Free cash flow margin | — | 10.5% |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -55.0% | -8.6% |
| Gross margin | — | 80.8% |
| Operating margin | — | -4.2% |
| Net debt / EBITDA | 0.59x | 6.22x |
Figures are as reported by each company; latest fiscal year shown.
Where Lexeo Therapeutics, Inc. Common Stock's cash went (FY2025)
- Capital spending
- $397000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Mirum Pharmaceuticals, Inc.'s cash went (FY2025)
- Capital spending
- $954000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free